<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04142723</url>
  </required_header>
  <id_info>
    <org_study_id>Alcoholic Hepatitis</org_study_id>
    <nct_id>NCT04142723</nct_id>
  </id_info>
  <brief_title>Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN).</brief_title>
  <official_title>Alcoholic Hepatitis in Latin-America: A Prospective and Multicentric Study (AH-LATIN).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pontificia Universidad Catolica de Chile</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ALEH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nacional Hipolito</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Goyoneche Arequipa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nacional Edgardo Rebagliati Martins</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>HBCASE</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Regional Honorio Delgado Arequipa Peru</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Nacional Daniel Alcides Carrión - Callao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Gastroenterología</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Docente Clinico Quirurgico:Manuel Piti Fajardo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Clínicas D. N. Avellaneda</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Padilla. Tucuman</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Pablo Soria. Jujuy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FUNDACIÓN SAYANI</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Italiano Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rosario</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Gastroenterología Dr Carlos Bonorino Udaondo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Austral de Buenos Aires</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Francisco Alfonso Solís Galindo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centro de Investigación en Enfermedades Hepáticas y Gastroenterología</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General de Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Eugenio Espejo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Especialidades de las FF.AA Quito</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Carlos Andrade Marín</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital General San Juan de Dios</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Roosevelt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Vicente Fundación Medellín</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinica Universitaria Colombia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Vicente Fundación - Rionegro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundacion Cardioinfantil</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Pablo Tobon Uribe. Univ. De Antioquia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fundação Hospital Adriano Jorge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital do Rocio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital das Clinacas Riberao Preto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidade Estadual Paulista (UNESP) - Botucatu/São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>FUNDHACRE- Serviço de Assistência Especializada- Acre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Getúlio Vargas - Teresina/Piauí</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital do Servidor Público Estadual - São Paulo/São Paulo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Federal de Bonsucesso - Rio de Janeiro/Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CHP/ Cl Davila / HCUH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Juan de Dios</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Sotero Del Rio</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital San Borja-Arriaran</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Chile</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Clinico Universidad Catolica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Concepcion</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Escuela</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Pontificia Universidad Catolica de Chile</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to determine the prevalence of AH in addition to its
      clinical characteristics and in-hospital mortality of patients that are hospitalized for AH
      in different hospitals across Latin American countries This study is carried out in different
      health centers throughout America, with all the countries belonging to the Latin American
      Association for the study of liver diseases (ALEH) more Canada and United States This would
      allow us to better understand the epidemiology of AH in our region and thus implement
      prevention measures with more solid data. Importantly, this would allow us to optimize
      therapeutic measures
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is sponsored and organized by the &quot;group Latin American of interest special in the
      study of the disease hepatic Alcohol&quot; (ALEH-GLEHA), belonging to the Latin American
      Association for the study of the hepatic illnesses (ALEH), which is an association non-profit
      that has nearly 1,000 members from most of the countries of Latin America.

      All patients admitted to the hospital with suspected alcoholic hepatitis will be evaluated to
      see if they can be included in the study. Patients will be enrolled according with the
      inclusion and exclusion criteria.

      The investigators will take a blood sample to be analyzed as part of the necessary data
      record, for the study of genes and identification of proteins involved in the development,
      evolution and prognosis of alcoholic hepatitis.

      If the medical doctor had instructed to perform a liver biopsy, voluntarily the investigators
      will ask to participants donate a small share of the surplus of histological sample To
      achieve this, it is necessary to generate a data bank of clinical information and biological
      samples (blood, urine, bile, stools, salivary sample or tissue samples) that allows studying
      the various factors involved in the development and prognosis of this disease in the
      countries of the Americas.

      The investigators will make a clinical follow-up for a year, consisting of phone calls to
      complete a questionnaire about participant's health. These calls will be made in month 1, 3,
      6 and 12 subsequent to participant's hospital discharge.

      The data collected are identified by a code and only the study physicians can correlate the
      data with the participants and medical history, so the participant's identity will not be
      shared.

      There is no financial compensation associated with the study
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">June 20, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Crossover</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>4 Years</target_duration>
  <primary_outcome>
    <measure>Number of subjects hospitalized with alcoholic hepatitis who die at 30, 60 and 90 days.</measure>
    <time_frame>90 days</time_frame>
    <description>To determine the clinical characteristics, complications and in-hospital mortality of patients who are hospitalized for alcoholic hepatitis in different establishments in America.
To achieve this, it is necessary to generate a data bank of clinical information and biological samples (blood, urine, bile, stools, salivary sample or tissue samples) that allows studying the various factors involved in the development and prognosis of this disease in the countries of the Americas. This will help us to know aspects of the highest prevalence and mortality from alcoholic hepatitis in Latin Americans in comparison to other regions of the world and useful information in the prevention and early diagnosis of this disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of subjects hospitalized with alcoholic hepatitis who develop complications (infection, gastrointestinal bleeding, renal failure, etc.)</measure>
    <time_frame>4 years</time_frame>
    <description>Inquire about the incidence of infections and prevalence of infections resistant to antibiotics in patients hospitalized for alcoholic hepatitis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with alcoholic hepatitis who are cataloged as responders by Lille score.</measure>
    <time_frame>4 years</time_frame>
    <description>with the data bank researches will be able to track patients through health questionnaires</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Model of End-Stage Liver Disease (MELD) score at day 0, 30, 60 and 90.</measure>
    <time_frame>4 years</time_frame>
    <description>with the data bank researches will be able to track patients through health questionnaires</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Hepatitis, Alcoholic</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood withdraw</intervention_name>
    <description>venous blood sampling</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Consumption of more than 3 drinks per day in women and more than 4 drinks per day in men
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Consumption of more than 3 drinks per day (40 g) in women and more than 4 drinks per
             day (50-60 g) in men.

          2. Excessive alcohol consumption for more than 5 years in a row or interrupted.

          3. No more than 60 days of abstinence before the onset of jaundice.

          4. Bilirubin levels &gt; 3 mg / dL (&gt; 50 μmol / L), AST&gt; 50 IU / mL, AST / ALT ratio&gt; 1.5.

          5. Absence of other causes of hepatic disease.

        Exclusion Criteria:

          1. Age &lt; 18 years

          2. Pregnancy or lactation

          3. Alcohol abstinence for more than 60 days before the event that led to hospitalization.

          4. Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels beyond
             400 IU/ml.

          5. Presence of drug-induced liver injury (DILI), ischemic hepatitis, biliary duct
             obstruction, viral hepatitis, autoimmune hepatitis or Wilson's disease.

          6. Hepatocellular carcinoma beyond the Milan criteria (ie, a single lesion &lt; 5 cm or no
             more than 3 lesions, the largest of which measures ≤ 3 cm).

          7. Extrahepatic neoplasia with a life expectancy of less than 6 months.

          8. History of severe extrahepatic disease (eg, chronic kidney failure requiring
             hemodialysis, severe heart disease (NYHA class ≥ 3), severe chronic lung disease that
             confers a survival of less than 6 months.

          9. Patients who cannot provide informed consent and that lack a responsible legal
             substitute.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>juan pablo p arab, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pontificia Universidad Catolica de Chile</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Juan pablo p arab, MD</last_name>
    <phone>56223543845</phone>
    <phone_ext>3845</phone_ext>
    <email>jparab@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Juan Pablo P Roblero, MD</last_name>
    <phone>56223543845</phone>
    <phone_ext>3845</phone_ext>
    <email>jroblero@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Clinico Unversidad Catolica de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>juan p arab, MD</last_name>
      <phone>56223543845</phone>
      <phone_ext>3845</phone_ext>
      <email>jparab@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>juan p roblero, MD</last_name>
      <phone>56223543845</phone>
      <phone_ext>3845</phone_ext>
      <email>jproblero@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Chile</country>
  </location_countries>
  <link>
    <url>https://alehlatam.org/2019/07/hepatitis-alcoholica-en-america-latina-un-estudio-prospectivo-y-multicentrico-ah-latin/</url>
    <description>invitation to participate</description>
  </link>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2019</study_first_submitted>
  <study_first_submitted_qc>October 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 29, 2019</study_first_posted>
  <last_update_submitted>October 25, 2019</last_update_submitted>
  <last_update_submitted_qc>October 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alcoholic, liver disease, cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

